Technical Analysis for MEIP - MEI Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -0.47% | |
| Gapped Down | Weakness | -0.47% | |
| New 52 Week Low | Weakness | 0.49% | |
| 20 DMA Resistance | Bearish | -1.71% | |
| MACD Bullish Signal Line Cross | Bullish | -1.71% | |
| Oversold Stochastic | Weakness | -1.71% | |
| Wide Bands | Range Expansion | 2.79% | |
| Gapped Up | Strength | 2.79% | |
| Oversold Stochastic | Weakness | 2.79% | |
| Inside Day | Range Contraction | 2.79% |
| Alert | Time |
|---|---|
| Possible NR7 | 4 minutes ago |
| Possible Inside Day | 4 minutes ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| 10 DMA Resistance | about 3 hours ago |
| Gap Down Partially Closed | about 4 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
MEI Pharma, Inc. Description
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Clinical Development Treatment Of Cancer Virotherapy Novogen Histone Deacetylase Inhibitor Refractory Solid Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.9099 |
| 52 Week Low | 2.99 |
| Average Volume | 20,512 |
| 200-Day Moving Average | 4.89 |
| 50-Day Moving Average | 3.62 |
| 20-Day Moving Average | 3.20 |
| 10-Day Moving Average | 3.10 |
| Average True Range | 0.18 |
| RSI (14) | 39.76 |
| ADX | 21.03 |
| +DI | 16.51 |
| -DI | 18.59 |
| Chandelier Exit (Long, 3 ATRs) | 3.33 |
| Chandelier Exit (Short, 3 ATRs) | 3.54 |
| Upper Bollinger Bands | 3.48 |
| Lower Bollinger Band | 2.92 |
| Percent B (%b) | 0.42 |
| BandWidth | 17.52 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.19 |
| MACD Histogram | 0.0259 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.39 | ||||
| Resistance 3 (R3) | 3.38 | 3.29 | 3.35 | ||
| Resistance 2 (R2) | 3.29 | 3.24 | 3.30 | 3.33 | |
| Resistance 1 (R1) | 3.23 | 3.20 | 3.26 | 3.24 | 3.32 |
| Pivot Point | 3.14 | 3.14 | 3.16 | 3.15 | 3.14 |
| Support 1 (S1) | 3.08 | 3.09 | 3.11 | 3.09 | 3.00 |
| Support 2 (S2) | 2.99 | 3.05 | 3.00 | 2.99 | |
| Support 3 (S3) | 2.93 | 2.99 | 2.97 | ||
| Support 4 (S4) | 2.94 |
